A new, once-a-month shot shows promise for the treatment of schizophrenia. The new drug is called paliperidone palmitate. It's an injectable form of the second-generation, or "atypical," antipsychotic medication Invega. A study pitting injectable paliperidone palmitate against placebo was halted early because of its clear benefit in preventing relapses, says David Hough, MD. Hough is a psychiatrist who led the study while at Johnson & Johnson, which makes paliperidone palmitate and funded the work.

Full story: medicinenet.com